Head-To-Head Analysis: TherapeuticsMD (TXMD) & Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals (NASDAQ:CRVS) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Volatility & Risk

Corvus Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500.

Institutional & Insider Ownership

85.8% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of TherapeuticsMD shares are held by institutional investors. 39.5% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 22.9% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Corvus Pharmaceuticals and TherapeuticsMD, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals 0 0 4 0 3.00
TherapeuticsMD 0 0 4 0 3.00

Corvus Pharmaceuticals currently has a consensus target price of $14.33, suggesting a potential upside of 253.04%. TherapeuticsMD has a consensus target price of $16.25, suggesting a potential upside of 272.71%. Given TherapeuticsMD’s higher possible upside, analysts plainly believe TherapeuticsMD is more favorable than Corvus Pharmaceuticals.

Profitability

This table compares Corvus Pharmaceuticals and TherapeuticsMD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corvus Pharmaceuticals N/A -38.02% -35.29%
TherapeuticsMD -823.71% -127.34% -71.34%

Valuation & Earnings

This table compares Corvus Pharmaceuticals and TherapeuticsMD’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corvus Pharmaceuticals N/A N/A -$46.94 million N/A N/A
TherapeuticsMD $16.10 million 65.31 -$132.62 million ($0.59) -7.39

Corvus Pharmaceuticals has higher earnings, but lower revenue than TherapeuticsMD.

Summary

Corvus Pharmaceuticals beats TherapeuticsMD on 6 of the 9 factors compared between the two stocks.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc. operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.